Navigation Links
Auxilium Pharmaceuticals, Inc. Announces First Patients Dosed in XIAFLEX® Phase Ib Cellulite Study
Date:1/26/2012

visit http://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the potential for XIAFLEX to treat edematous fibrosclerotic panniculopathy, commonly known as cellulite; the timing of release of topline results from the phase Ib study of XIAFLEX for the treatment of cellulite; the number of people with cellulite and the market opportunity represented by that number ; and products in development for Peyronie's disease, Frozen Shoulder syndrome and cellulite; and all other statements containing projections, statements of future performance or expectations, our beliefs or statements of plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). Forward-looking statements can generally be identified by words such as "believe," "appears," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," and other words and terms of similar meaning in connection with any discussion of projections, future performance or expectations, beliefs, plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). Actual results may differ materially from those reflected in these forward-looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, decisions by regulatory authorities as to whether and when to approve drug applications, and general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in Auxilium's Annual Report under the heading "Risk Factors" on Form 10-K for the year ended December 31, 2010 and the Company's
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
3. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
4. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
5. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
6. Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference
7. Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance
8. Auxilium Pharmaceuticals to Present at the 2011 Citi Annual Global Healthcare Conference
9. Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. Auxilium Pharmaceuticals, Inc. Completes Enrollment of XIAFLEX® Phase III Double-Blind Studies for Peyronies Disease
11. Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... OAKS, Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) ... (STudy evaluating effect of RomosozUmab Compared with Teriparatide ... for fracture pReviously treated with bisphosphonatE therapy). The ... statistically significant difference in favor of romosozumab in ...
(Date:9/1/2015)... Emerus Holdings, a national and innovative ... diagnostic care in partnership with leading health systems, ... to receive a strategic investment from Welsh, Carson, ... care investment firm. Emerus partners with ... and ambulatory clinical services to communities across a ...
(Date:9/1/2015)... 1, 2015  Edwards Lifesciences Corporation (NYSE: EW ... valves and hemodynamic monitoring, is scheduled to present at ... Hyatt Regency Boston in Boston, Massachusetts ... Michael A. Mussallem , Edwards Lifesciences, chief executive officer, ... a company discussion with conference attendees at 10:10 a.m. ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3
... at the Fourth Annual Medical Product Outsourcing (MPO) Symposium ... the outsourcing relationship with its "open-book pricing" roundtable discussion ... manufacturers are trying to limit cost by requiring suppliers ... director of marketing at Arc-Tronics. "The debate centers on ...
... Md., Oct. 19 The U.S. Food and ... for the prevention of stroke and blood clots ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... fibrillation, which affects more than 2 million Americans, ...
Cached Medicine Technology:MPO Symposium Panel Discussion to Address Open-Book Pricing and Its Effect on Long-Term Performance 2FDA Approves Pradaxa to Prevent Stroke in People With Atrial Fibrillation 2
(Date:9/1/2015)... ... September 01, 2015 , ... Stress ... stress created from everyday life changes can lead to very serious, life-altering events. ... for coping with stress. Herbal supplement manufacturer MediHerb has coupled therapeutic ...
(Date:9/1/2015)... ... , ... Georgia State University and its partners have introduced ... sexual assaults on their campuses. , The free, evidence-based survey was developed by ... and student affairs professionals responding to calls by the Obama Administration to strengthen ...
(Date:9/1/2015)... London, UK (PRWEB) , ... September 01, 2015 ... ... of a vacuum that creates negative pressure inside a wound to remove exudates, ... market for treatment devices (comprising portable devices, stand-alone devices, disposable devices, and canisters, ...
(Date:9/1/2015)... ... , ... The Jerry Segal Classic to benefit the patients of Magee Rehabilitation ... in Lafayette Hill, PA. Over the past 26 years, the Classic, organized by the ... designed to support patients and their families during their time at Magee Rehabilitation Hospital. ...
(Date:9/1/2015)... Freeport, ME (PRWEB) , ... September 01, 2015 , ... ... a large, new study that followed men and women for 19 years and found ... those who did not take multivitamins. , The report is part of the September ...
Breaking Medicine News(10 mins):Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2
... JAZZ ) announced today that Robert Myers , the company,s President, will present at the Barclays Capital 2010 Global Healthcare Conference on Wednesday, March 24, 2010 ... ... ... ...
... A new exhibition hall dedicated to the discovery ... at the Smithsonian,s National Museum of Natural History. Based on ... Koch (pronounced "coke") Hall of Human Origins will open to ... 3 p.m. Wednesday, March 17, which also marks the ...
... been known that alcohol exposure is toxic to the developing ... problems. Now, a new report out of UCLA shows that ... combination of methamphetamine and alcohol may be even more ... issue of the Journal of Neuroscience , UCLA professor ...
... died soon after than those using Brilinta, study ... a trial comparing two anti-clotting drugs, patients given Brilinta ... than those given Plavix, researchers found. , Both drugs ... the more popular drug, has been linked to potentially ...
... , ... ... PRINCETON, N.J. , March 16 Statement of Betsy Ryan , President and CEO, New Jersey Hospital Association: , ... , ...
... For parents of children with multiple medical problems, keeping up ... medications can be overwhelming, especially for those in challenging socioeconomic ... wind up using the emergency room, the country,s most expensive ... But a growing concept in health care ...
Cached Medicine News:Health News:Jazz Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference 2Health News:New Exhibition Hall Devoted to Human Origins Opens at National Museum of Natural History 2Health News:New Exhibition Hall Devoted to Human Origins Opens at National Museum of Natural History 3Health News:New Exhibition Hall Devoted to Human Origins Opens at National Museum of Natural History 4Health News:New Exhibition Hall Devoted to Human Origins Opens at National Museum of Natural History 5Health News:New Exhibition Hall Devoted to Human Origins Opens at National Museum of Natural History 6Health News:Researchers ID brain abnormalities in children exposed to methamphetamine in utero 2Health News:Researchers ID brain abnormalities in children exposed to methamphetamine in utero 3Health News:Newer Blood Thinner Beats Plavix for Bypass Patients 2Health News:Newer Blood Thinner Beats Plavix for Bypass Patients 3Health News:NJHA: Charity Care Must Be a Priority as Uninsured Burden Grows 2Health News:Novel 'medical home' program for pediatric patients, families cuts ER visits in half 2Health News:Novel 'medical home' program for pediatric patients, families cuts ER visits in half 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: